Center for Genomic Medicine and Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA.
Int J Mol Sci. 2024 Aug 28;25(17):9343. doi: 10.3390/ijms25179343.
Preeclampsia (PE) is a major cause of maternal and neonatal morbidity and mortality worldwide, with the placenta playing a central role in disease pathophysiology. This review synthesizes recent advancements in understanding the molecular mechanisms underlying PE, focusing on placental genes, proteins, and genetic variants identified through multi-omic approaches. Transcriptomic studies in bulk placental tissue have identified many dysregulated genes in the PE placenta, including the PE signature gene, Fms-like tyrosine kinase 1 (). Emerging single-cell level transcriptomic data have revealed key cell types and molecular signatures implicated in placental dysfunction and PE. However, the considerable variability among studies underscores the need for standardized methodologies and larger sample sizes to enhance the reproducibility of results. Proteomic profiling of PE placentas has identified numerous PE-associated proteins, offering insights into potential biomarkers and pathways implicated in PE pathogenesis. Despite significant progress, challenges such as inconsistencies in study findings and lack of validation persist. Recent fetal genome-wide association studies have identified multiple genetic loci associated with PE, with ongoing efforts to elucidate their impact on placental gene expression and function. Future directions include the integration of multi-omic data, validation of findings in diverse PE populations and clinical subtypes, and the development of analytical approaches and experimental models to study the complex interplay of placental and maternal factors in PE etiology. These insights hold promise for improving risk prediction, diagnosis, and management of PE, ultimately reducing its burden on maternal and neonatal health.
子痫前期 (PE) 是全球孕产妇和新生儿发病率和死亡率的主要原因,胎盘在疾病病理生理学中起着核心作用。本综述综合了近年来对 PE 相关分子机制的理解进展,重点关注通过多组学方法鉴定的胎盘基因、蛋白质和遗传变异。对大量胎盘组织的转录组学研究鉴定了 PE 胎盘中许多失调的基因,包括 PE 特征基因 Fms 样酪氨酸激酶 1 (Flt1)。新兴的单细胞水平转录组学数据揭示了与胎盘功能障碍和 PE 相关的关键细胞类型和分子特征。然而,研究之间存在很大的可变性,这突出表明需要标准化方法和更大的样本量来提高结果的可重复性。PE 胎盘的蛋白质组学分析鉴定了许多与 PE 相关的蛋白质,为 PE 发病机制中涉及的潜在生物标志物和途径提供了深入了解。尽管取得了重大进展,但研究结果的不一致性和缺乏验证仍然存在挑战。最近的胎儿全基因组关联研究已经确定了多个与 PE 相关的遗传位点,目前正在努力阐明它们对胎盘基因表达和功能的影响。未来的方向包括整合多组学数据、在不同的 PE 人群和临床亚型中验证研究结果,以及开发分析方法和实验模型来研究 PE 病因中胎盘和母体因素的复杂相互作用。这些见解有望改善 PE 的风险预测、诊断和管理,从而降低其对母婴健康的负担。